MDL | MFCD08460118 |
---|---|
Molecular Weight | 390.82 |
Molecular Formula | C14H23ClN6O5 |
SMILES | N[C@@H](C(C)C)C(OCC(OCN1C=NC2=C1N=C(N)NC2=O)CO)=O.[H]Cl |
Valganciclovir (hydrochloride), the L-valyl ester of ganciclovir, is actually a prodrug for ganciclovir. Valganciclovir is an antiviral medication used to treat cytomegalovirus infections. IC50 Value: Target: CMV in vitro: In cell culture model systems using Caco-2 cells for PEPT1 and SKPT cells for PEPT2, valganciclovir inhibited glycylsarcosine transport mediated by PEPT1 and PEPT2 with K(i) values (inhibition constant) of 1.68+/-0.30 and 0.043+/- 0.005 mM, respectively. The inhibition by valganciclovir was competitive in both cases [1]. in vivo: 37 patients were enrolled; 19 patients received treatment with VGV and 18 patients received treatment with GCV. The VGV was not inferior in efficacy to GCV as pre-emptive therapy, with rates of viral clearance at 28 days of 89.5% and 83%, respectively (P-value for non-inferiority = 0.030). Toxicities were similar between the 2 arms. No patients developed CMV disease [2]. Patients being treated with an alemtuzumab-containing regimen received prophylaxis with either valaciclovir 500 mg orally daily orvalganciclovir 450 mg orally twice daily. None of the 20 patients randomized to valganciclovir experienced CMV reactivation (P = .004) [3].
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT00031434 | National Institute of Allergy and Infectious Diseases (NIAID) |
Cytomegalovirus Infections
|
July 2002 | Phase 1|Phase 2 |
NCT00017784 | Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service |
Cytomegalovirus Retinitis|HIV Infections
|
Phase 3 | |
NCT00006145 | National Institute of Allergy and Infectious Diseases (NIAID) |
Cytomegalovirus Infections|HIV Infections
|
August 2000 | Phase 3 |
NCT00330018 | Hadassah Medical Organization |
Bone Marrow Transplantation|Cytomegalovirus
|
February 2006 | Phase 3 |
NCT00917826 | HemaQuest Pharmaceuticals Inc.|Boston University |
EBV Lymphomas|Lympho-proliferative Diseases
|
September 2008 | Phase 2 |
NCT00189150 | University of Michigan|Hoffmann-La Roche |
Kidney Transplant Recipient|Heart Transplant Recipient
|
April 2005 | Phase 4 |
NCT00372229 | Hoffmann-La Roche |
Cytomegalovirus Infections
|
May 2006 | Phase 3 |
NCT00090766 | Hoffmann-La Roche |
Cytomegalovirus Infections
|
May 2004 | Phase 2|Phase 3 |
NCT00364052 | Oregon Health and Science University |
Liver Transplantation
|
August 2006 | |
NCT00466817 | National Institute of Allergy and Infectious Diseases (NIAID) |
Cytomegalovirus Infection
|
June 2008 | Phase 3 |
NCT00828503 | Marcus Saemann|Medical University of Vienna |
Cytomegalovirus Disease
|
December 2008 | Phase 2 |
NCT02606266 | Assistance Publique - Hôpitaux de Paris |
Congenital Cytomegalovirus (CMV)
|
July 11, 2017 | Phase 2|Phase 3 |
NCT02927067 | Shire|Takeda Development Center Americas, Inc.|Takeda |
Cytomegalovirus (CMV)
|
April 14, 2017 | Phase 3 |
NCT00966836 | University of Bologna |
Heart Transplantation|Cardiac Allograft Vasculopathy|Cytomegalovirus Infection
|
April 2009 | Phase 3 |
NCT01655212 | Dr. Ann C.T.M. Vossen|Stichting Nuts Ohra|Leiden University Medical Center |
Congenital Cytomegalovirus Infection|Sensorineural Hearing Loss
|
June 2012 | Phase 3 |
NCT00275314 | University of Pittsburgh|Hoffmann-La Roche |
Kidney Transplant
|
February 2006 | Phase 3 |
NCT03698435 | University Medical Center Groningen |
Cytomegalovirus Infections
|
May 25, 2018 | |
NCT00217503 | National Cancer Institute (NCI) |
Lymphoma
|
July 2005 | Phase 2 |
NCT03915366 | Hospital Universitario 12 de Octubre|University Hospital, Bordeaux|Institut National de la Santé Et de la Recherche Médicale, France|PENTA Foundation|Centre Hospitalier Cocody|Malawi-Liverpool-Wellcome Trust Clinical Research Programme|Eduardo Mondlane University|Centro de Investigação em Saúde de Manhiça|Stichting Katholieke Universiteit|Barcelona Institute for Global Health|University of Lincoln|Makerere University|University Teaching Hospital, Lusaka, Zambia|University of Zimbabwe |
Pneumonia|HIV+AIDS|Tuberculosis|Cytomegalovirus Infections
|
March 1, 2020 | Phase 2|Phase 3 |
NCT00264290 | University of California, San Francisco|Roche Pharma AG |
HIV Infections|Cytomegalovirus Infections
|
August 2006 | Phase 4 |
NCT01165580 | Hoffmann-La Roche |
Cytomegalovirus Infections, Heart Transplantation
|
May 2011 | Phase 1 |
NCT00431353 | Hoffmann-La Roche |
Cytomegalovirus Infections
|
April 2004 | Phase 4 |
NCT01255644 | Medical University of Vienna |
Chronic Lymphocytic Leukemia
|
December 2010 | Phase 4 |
NCT00478465 | Stanford University |
Chronic Fatigue Syndrome
|
May 2007 | Phase 1|Phase 2 |
NCT00992732 | HemaQuest Pharmaceuticals Inc. |
Lymphoid Malignancies|Lymphoproliferative Disorders
|
May 2010 | Phase 2 |
NCT00092222 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Lymphoproliferative Disorder|HHV-8|Malignancy|HIV
|
October 28, 2004 | Phase 2 |
NCT02439957 | Chimerix |
Cytomegalovirus Disease|Kidney Transplant Infection
|
September 2015 | Phase 3 |
NCT00002222 | Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service |
Cytomegalovirus Retinitis|HIV Infections
|
Not Applicable | |
NCT05041426 | Fernanda P Silveira, MD, MS|Merck Sharp & Dohme LLC|University of Pittsburgh |
Lung Transplant|CMV
|
December 6, 2021 | Phase 2 |
NCT00002377 | Hoffmann-La Roche |
Cytomegalovirus Retinitis|HIV Infections
|
January 1997 | Phase 3 |
NCT00227370 | Scott Palmer|Roche Pharma AG|Duke University |
Cytomegalovirus Infections
|
July 2003 | Phase 3 |
NCT00237653 | University Hospital, Grenoble |
Cytomegalovirus Infections|Inflammatory Bowel Diseases
|
February 2004 | Phase 3 |
NCT03699254 | Maimónides Biomedical Research Institute of Córdoba|Instituto de Salud Carlos III |
Transplantation Infection|Cytomegalovirus Infections
|
April 5, 2019 | Phase 3 |
NCT01552369 | National Institute of Allergy and Infectious Diseases (NIAID) |
Cytomegalovirus Infection
|
October 29, 2012 | Phase 4 |
NCT00275665 | Mayo Clinic|Roche Pharma AG|Fred Hutchinson Cancer Center|City of Hope National Medical Center|University of Florida|University of Michigan |
Bone Marrow Stem Cell Transplant
|
November 2001 | Phase 3 |
NCT02761291 | Chang Gung Memorial Hospital|TTY Biopharm |
Nasopharyngeal Carcinoma
|
May 2016 | Phase 1 |
NCT03631316 | Luis Eduardo Morales Buenrostro|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
Kidney Transplantation|Cytomegalovirus Infections|Pharmacokinetics|Therapeutic Equivalency
|
March 1, 2018 | Not Applicable |
NCT00141037 | National Institute of Allergy and Infectious Diseases (NIAID)|Astellas Pharma Inc|Hoffmann-La Roche |
Kidney Diseases|Kidney Transplantation|Kidney Transplant|Renal Transplantation|Renal Transplant
|
March 2004 | Phase 1|Phase 2 |
NCT03107871 | Albert Park|National Institute on Deafness and Other Communication Disorders (NIDCD)|Genentech, Inc.|University of Utah |
Cmv Congenital|CMV|Congenital Cmv|SNHL|Sensorineural Hearing Loss
|
August 31, 2018 | Phase 2 |
NCT02871401 | Vanderbilt University Medical Center|Genentech, Inc. |
Idiopathic Pulmonary Fibrosis
|
January 3, 2018 | Phase 1 |
NCT00294515 | Hoffmann-La Roche |
Cytomegalovirus Infections
|
March 31, 2006 | Phase 3 |
NCT01376804 | Hoffmann-La Roche |
Kidney Transplantation, Cytomegalovirus Infections
|
July 31, 2011 | Phase 4 |
NCT03511118 | Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
Lactating Women on Select DOI|Breastfed Infants of Mothers on Select DOI
|
October 4, 2018 | |
NCT01509404 | Medical University of South Carolina|CSL Behring |
Cytomegalovirus Disease
|
November 2011 | Phase 4 |
NCT02297854 | Dr. Reddy´s Laboratories Limited |
Healthy
|
July 2011 | Phase 1 |
NCT04116411 | Cecilia Soderberg-Naucler|Karolinska University Hospital|Karolinska Institutet |
Glioblastoma Multiforme
|
September 4, 2019 | Phase 2 |
NCT03301415 | National Institute of Allergy and Infectious Diseases (NIAID) |
Congenital Cytomegalovirus Infection
|
April 2, 2019 | Phase 2 |
NCT03443869 | Merck Sharp & Dohme LLC |
CMV Disease
|
May 3, 2018 | Phase 3 |
NCT03586284 | University of California, San Francisco|Huang Pacific Foundation|Khon Kaen University|King Chulalongkorn Memorial Hospital |
Cytomegalovirus Anterior Uveitis
|
March 15, 2020 | Phase 2|Phase 3 |
NCT00386412 | PETHEMA Foundation |
Cytomegalovirus Infection
|
November 2005 | Phase 2 |
NCT00562770 | M.D. Anderson Cancer Center|Roche Pharma AG |
Chronic Lymphocytic Leukemia|Leukemia
|
September 2003 | Phase 2 |
NCT05011058 | Viracta Therapeutics, Inc. |
Epstein-Barr Virus Associated Lymphoproliferative Disorder|EBV-Related PTLD|EBV Related Non-Hodgkin´s Lymphoma|Extranodal NK+T-cell Lymphoma|EBV-Positive DLBCL, Nos|EBV Associated Lymphoma|EBV-Related Hodgkin Lymphoma|EBV Related PTCL, Nos
|
May 28, 2021 | Phase 2 |
NCT01199562 | City of Hope Medical Center|National Cancer Institute (NCI) |
Hematopoietic+Lymphoid Cancer|Accelerated Phase Chronic Myelogenous Leukemia|Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK+T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Aplastic Anemia|Atypical Chronic Myeloid Leukemia, BCR-ABL Negative|Blastic Phase Chronic Myelogenous Leukemia|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Cytomegalovirus Infection|de Novo Myelodysplastic Syndromes|Essential Thrombocythemia|Extramedullary Plasmacytoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Isolated Plasmacytoma of Bone|Mast Cell Leukemia|Meningeal Chronic Myelogenous Leukemia|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Polycythemia Vera|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Primary Systemic Amyloidosis|Progressive Hairy Cell Leukemia, Initial Treatment|Prolymphocytic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia+Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides+Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Secondary Myelofibrosis|Splenic Marginal Zone Lymphoma|Stage 0 Chronic Lymphocytic Leukemia|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia+Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage I Mycosis Fungoides+Sezary Syndrome|Stage I Small Lymphocytic Lymphoma|Stage II Adult Hodgkin Lymphoma|Stage II Adult T-cell Leukemia+Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Multiple Myeloma|Stage II Mycosis Fungoides+Sezary Syndrome|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia+Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Mycosis Fungoides+Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia+Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides+Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Waldenstrom Macroglobulinemia
|
December 2010 | |
NCT00016068 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Infection
|
January 2001 | Phase 3 |
NCT01329185 | University of Minnesota |
EBV Viremia|CMV Viremia
|
June 2011 | Phase 2 |
NCT02973464 | First Affiliated Hospital Xi´an Jiaotong University |
Renal Transplant Recipients
|
June 2016 | |
NCT03397706 | Viracta Therapeutics, Inc. |
Epstein-Barr Virus Associated Lymphoma|Lymphoproliferative Disorders
|
March 29, 2018 | Phase 1|Phase 2 |
NCT02931539 | Shire|Takeda |
Cytomegalovirus (CMV)
|
December 22, 2016 | Phase 3 |
NCT01649869 | National Institute of Allergy and Infectious Diseases (NIAID) |
Cytomegalovirus Infection
|
February 24, 2015 | Phase 2 |
NCT01663740 | Hoffmann-La Roche |
Cytomegalovirus Infections
|
January 30, 2012 | Phase 4 |
NCT02005822 | Dr. Ann C.T.M. Vossen|Stichting Nuts Ohra|Leiden University Medical Center |
Congenital Cytomegalovirus Infection|Sensorineural Hearing Loss
|
October 22, 2013 | Phase 3 |
NCT00377741 | Hoffmann-La Roche |
Cytomegalovirus Infections
|
December 2004 | Phase 1 |
NCT04724447 | Laureate Institute for Brain Research, Inc. |
Major Depressive Disorder
|
November 23, 2021 | Phase 1|Phase 2 |
NCT00387530 | University of California, San Diego|National Cancer Institute (NCI) |
Gastric Cancer|Head and Neck Cancer|Lymphoma|Lymphoproliferative Disorder
|
May 2006 | Phase 2 |
NCT04064697 | Centre Hospitalier Universitaire de Saint Etienne|Ministry of Health, France |
Ulcerative Colitis, Unspecified
|
April 22, 2021 | Phase 3 |
NCT00034385 | National Institutes of Health Clinical Center (CC) |
Kidney Trasplant
|
April 24, 2002 | Phase 4 |
NCT01185223 | Pierrel Research Europe GmbH|Roche Pharma AG |
Allogeneic Stem Cell Transplantation
|
September 2010 | Phase 3 |
NCT03296553 | National Institute of Cancerología|Instituto Nacional de Enfermedades Respiratorias |
Kaposi Sarcoma|Human Immunodeficiency Virus|Immune Reconstitution Syndrome
|
October 1, 2015 | Phase 2 |
NCT01049633 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Type 1 Diabetes Mellitus
|
||
NCT01441063 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Castleman Disease|Multicentric Castleman Disease|Giant Lymph Node Hyperplasia
|
September 13, 2011 | Phase 2 |
NCT00400322 | Karolinska Institutet|Karolinska University Hospital |
Glioblastoma Multiforme|Cytomegalovirus Infection
|
August 2006 | Not Applicable |
NCT02503982 | Rabin Medical Center |
Infection in Solid Organ Transplant Recipients
|
December 2014 | Phase 4 |
NCT00194467 | University of Washington|Hoffmann-La Roche |
Human Herpesvirus 8
|
December 2002 | Phase 2 |
NCT01972035 | University of Minnesota |
Transplantation Infection|Epstein-Barr Virus Infections|Cytomegalovirus Infections
|
August 1, 2014 | Phase 2 |
NCT01446445 | Nuria Lloberas|Ministerio de Sanidad, Servicios Sociales e Igualdad|Hospital Universitari de Bellvitge |
Infection in Solid Organ Transplant Recipients
|
December 2011 | Phase 4 |
NCT00374686 | Washington University School of Medicine|Hoffmann-La Roche |
Cytomegalovirus Infection
|
March 2003 | Not Applicable |
NCT00241345 | Washington University School of Medicine |
Cytomegalovirus Infections
|
June 2004 | Phase 3 |
NCT05166577 | Viracta Therapeutics, Inc. |
Nasopharyngeal Carcinoma|EBV-Related Gastric Carcinoma|EBV-Related Leiomyosarcoma|EBV Related Carcinoma|EBV-Related Sarcoma
|
October 7, 2021 | Phase 1|Phase 2 |
NCT05238220 | Piedmont Healthcare|ViraCor Laboratories |
Kidney Transplant; Complications
|
January 4, 2021 | |
NCT00361933 | University of Washington|Hoffmann-La Roche |
Giant Lymph Node Hyperplasia
|
December 2008 | Phase 4 |
NCT02439970 | Chimerix |
Cytomegalovirus Disease
|
September 2015 | Phase 3 |
NCT02370758 | University Health Network, Toronto |
Cytomegalovirus Viraemia
|
November 2014 | Not Applicable |
NCT02296723 | Dr. Reddy´s Laboratories Limited |
Healthy
|
July 2011 | Phase 1 |
NCT00096538 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|New York Presbyterian Hospital|Weill Medical College of Cornell University|University of North Carolina, Chapel Hill |
Sarcoma
|
April 2004 | Not Applicable |
Solid
Room temperature in continental US; may vary elsewhere.
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
DMSO : 50 mg/mL ( 127.94 mM ; Need ultrasonic)
H 2 O : ≥ 50 mg/mL ( 127.94 mM )
* "≥" means soluble, but saturation unknown.
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.5587 mL | 12.7936 mL | 25.5872 mL |
5 mM | 0.5117 mL | 2.5587 mL | 5.1174 mL |
10 mM | 0.2559 mL | 1.2794 mL | 2.5587 mL |
Add each solvent one by one: PBS
Solubility: 100 mg/mL (255.87 mM); Clear solution; Need ultrasonic
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution